207 related articles for article (PubMed ID: 36585067)
1. Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex.
Farges D; Sigg N; Ville D; Martin L
Arch Pediatr; 2022 Dec; 29(5S):5S20-5S24. PubMed ID: 36585067
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin and rapalogs for tuberous sclerosis complex.
Sasongko TH; Ismail NF; Zabidi-Hussin Z
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011272. PubMed ID: 27409709
[TBL] [Abstract][Full Text] [Related]
3. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
Dill PE; De Bernardis G; Weber P; Lösch U
Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875
[TBL] [Abstract][Full Text] [Related]
4. Treatment of tuberous sclerosis complex manifestations in children with mTOR inhibitors.
Yeşil Ş; Kurucu B; Hamamcı MB; Yılmaz Ş; Şahin G
Childs Nerv Syst; 2024 Mar; 40(3):831-837. PubMed ID: 37947859
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
[TBL] [Abstract][Full Text] [Related]
7. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
Boggarapu S; Roberds SL; Nakagawa J; Beresford E
Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
[TBL] [Abstract][Full Text] [Related]
8. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
9. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
Somers MJ; Paul E
J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
[TBL] [Abstract][Full Text] [Related]
10. Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex-An update.
Balestri R; Rizzoli L; Pedrolli A; Urru SAM; Rech G; Neri I; Girardelli CR; Magnano M
J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):474-487. PubMed ID: 36300771
[TBL] [Abstract][Full Text] [Related]
11. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature.
Jóźwiak S; Sadowski K; Kotulska K; Schwartz RA
Pediatr Neurol; 2016 Aug; 61():21-7. PubMed ID: 27222056
[TBL] [Abstract][Full Text] [Related]
12. Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.
Wang S; Liu Y; Wei J; Zhang J; Wang Z; Xu Z
Pediatr Dermatol; 2017 Sep; 34(5):572-577. PubMed ID: 28771801
[TBL] [Abstract][Full Text] [Related]
13. A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium- and long-term efficacy and safety of topical rapamycin.
Sigg N; Fouquet J; Morin D; Farges D; Vrignaud S; Martin L
Ann Dermatol Venereol; 2023 Dec; 150(4):270-273. PubMed ID: 37821253
[TBL] [Abstract][Full Text] [Related]
14. Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report.
Tarasewicz A; Dębska-Ślizień A; Bułanowski M; Więcek A; Rutkowski B
Transplant Proc; 2014 Oct; 46(8):2912-5. PubMed ID: 25380949
[TBL] [Abstract][Full Text] [Related]
15. Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence.
Cortell Fuster C; Martínez Gómez MA; Cercós Lleti AC; Climente Martí M
J Dermatolog Treat; 2022 Jun; 33(4):1804-1810. PubMed ID: 33821748
[TBL] [Abstract][Full Text] [Related]
16. Perfect match: mTOR inhibitors and tuberous sclerosis complex.
Luo C; Ye WR; Shi W; Yin P; Chen C; He YB; Chen MF; Zu XB; Cai Y
Orphanet J Rare Dis; 2022 Mar; 17(1):106. PubMed ID: 35246210
[TBL] [Abstract][Full Text] [Related]
17. A Review of Topical Sirolimus for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex.
Dao DD; Pixley JN; Akkurt ZM; Feldman SR
Ann Pharmacother; 2024 Apr; 58(4):428-433. PubMed ID: 37386842
[TBL] [Abstract][Full Text] [Related]
18. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
Franz DN; Capal JK
Orphanet J Rare Dis; 2017 Mar; 12(1):51. PubMed ID: 28288694
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients.
Malissen N; Vergely L; Simon M; Roubertie A; Malinge MC; Bessis D
J Am Acad Dermatol; 2017 Sep; 77(3):464-472.e3. PubMed ID: 28502378
[TBL] [Abstract][Full Text] [Related]
20. Possible prevention of tuberous sclerosis complex lesions.
Kotulska K; Borkowska J; Jozwiak S
Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]